24 month PANGAEA: a 5-year non-interventional study of safety, efficacy and pharmacoeconomic data for fingolimod patients in daily clinical practice

被引：0
|
作者：
Ziemssen, T. [1 ]
Fuchs, A. [2 ]
Schwarz, H-J [3 ]
van Lokven, T. [2 ]
Cornelissen, C. [2 ]
机构：
[1] Karl Gustav Carus Univ Hosp, Ctr Clin Neurosci, Dresden, Germany
[2] Novartis Pharma GmbH, Nurnberg, Germany
[3] Kantar Hlth, Munich, Germany
来源：
MULTIPLE SCLEROSIS JOURNAL | 2014年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P107
引用
收藏
页码：115 / 116
页数：2
相关论文
共 50 条
  • [21] PANGAEA: The average German fingolimod patient. Demographics and baseline characteristics from a 5 year non-interventional study of RRMS patients treated with fingolimod
    Ziemssen, T.
    Albrecht, H.
    Klotz, L.
    Schmidt, S.
    Schwarz, H-J
    Tackenberg, B.
    Cornelissen, C.
    EUROPEAN JOURNAL OF NEUROLOGY, 2015, 22 : 620 - 620
  • [22] The PANGAEA study design - a prospective, multicenter, non-interventional, long-term study on fingolimod for the treatment of multiple sclerosis in daily practice
    Ziemssen, Tjalf
    Kern, Raimar
    Cornelissen, Christian
    BMC NEUROLOGY, 2015, 15
  • [23] 5 years safety experience with fingolimod in real world: results from PANGAEA, a non-interventional study of RRMS patients treated in Germany
    Ziemssen, T.
    Albrecht, H.
    Haas, J.
    Klotz, L.
    Lang, M.
    Lassek, C.
    Schmidt, S.
    Tackenberg, B.
    Cornelissen, C.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 630 - 630
  • [24] The PANGAEA study design – a prospective, multicenter, non-interventional, long-term study on fingolimod for the treatment of multiple sclerosis in daily practice
    Tjalf Ziemssen
    Raimar Kern
    Christian Cornelissen
    BMC Neurology, 15
  • [25] Safety of fingolimod in RRMS patients treated for up to 5 years in real world: interim results from the non-interventional PANGAEA study
    Ziemssen, T.
    Albrecht, H.
    Haas, J.
    Klotz, L.
    Lang, M.
    Lassek, C.
    Schmidt, S.
    Tackenberg, B.
    Cornelissen, C.
    Effle, B.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 294 - 295
  • [26] 5 years PANGAEA: Effectiveness of fingolimod in daily clinical practice of RRMS patients in Germany
    Ziemssen, T.
    Albrecht, H.
    Haas, J.
    Klotz, L.
    Lang, M.
    Lassek, C.
    Schmidt, S.
    Tackenberg, B.
    Cornelissen, C.
    EUROPEAN JOURNAL OF NEUROLOGY, 2017, 24 : 657 - 657
  • [27] PANGAEA: Post-Authorization Non-interventional German sAfety study of GilEnyA in relapsing-remitting multiple sclerosis (RRMS) patients: A 24-month interim analysis of a German five-year fingolimod registry study
    Ziemssen, T.
    Diaz-Lorente, M.
    Fuchs, A.
    Cornelissen, C.
    JOURNAL OF NEUROLOGY, 2014, 261 : S444 - S444
  • [28] PANGAEA: Post-Authorization Non-interventional German sAfety study of GilEnyA in relapsing-remitting multiple sclerosis (RRMS) patients: A 24-month interim analysis of a German five-year fingolimod registry study
    Ziemssen, T.
    Diaz-Lorente, M.
    Fuchs, A.
    Cornelissen, C.
    EUROPEAN JOURNAL OF NEUROLOGY, 2014, 21 : 685 - 685
  • [29] Study design of a non-interventional registry study to establish long-term safety and pharmaco-economic data on fingolimod (Gilenya®) in multiple sclerosis patients (PANGAEA)
    van Lokven, T.
    Kempcke, R.
    Ziemssen, T.
    Meergans, M.
    MULTIPLE SCLEROSIS JOURNAL, 2011, 17 : S213 - S214
  • [30] Utilisation, efficacy and safety of voriconazole: prospective, non-interventional study on treatment of IFIs in clinical practice
    Heinz, Werner J.
    Silling, Gerda
    Boehme, Angelika
    CURRENT MEDICAL RESEARCH AND OPINION, 2011, 27 (02) : 335 - 342
12345